17 publications
Name | Date | Type | Actions |
---|---|---|---|
Sales 3rd quarter 2023: 136M€ The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories. |
26/10/2023 | Public releases | |
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
07/09/2023 | Public releases | |
Q1 2023 Sales: €145M Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates. |
20/04/2023 | Public releases | |
Availability of the 2022 universal registration document On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
13/04/2023 | Public releases | |
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
23/03/2023 | Public releases | |
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) |
18/01/2023 | Public releases | |
Vetoquinol et nippon Zenyaku Kogyo Co. ltd. signent un accord de joint-venture au Japon Vetoquinol and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name “Zenoaq”, announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan. |
03/12/2015 | Public releases | |
September 2015 year-to-date sales up 8.7% to €251.8 million Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%. |
22/10/2015 | Public releases | |
VETOQUINOL launches UPCARD©, an innovative drug for congestive heart failure in dogs Vétoquinol continues the deployment of its reference products with the European launch of UPCARD©, an innovative drug designed to treat congestive heart failure in dogs. |
14/09/2015 | Public releases | |
First half 2015 sales €167.2m, up 11.9% The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements. |
30/07/2015 | Public releases |